KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co.[1][2][3] Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.[4]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
References
edit- ^ "20歳以上65歳未満の健康成人、及び65歳以上の健康な高齢者を対象に、COVID-19に対するワクチン（KD-414）の安全性及び免疫原性を検討するための、プラセボを対照とする多施設共同二重盲検ランダム化並行群間比較試験". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 7 May 2021.
- ^ "Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate". Reuters. 22 March 2021.
- ^ "18歳以上の健康な日本人を対象に、COVID-19に対するワクチン（KD-414）を2回接種した際の免疫原性及び安全性を確認する多施設共同非盲検非対照試験。". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 22 October 2021.
- ^ Tanishima M, Ibaraki K, Kido K, Nakayama S, Ata K, Nakamura H, et al. (29 June 2022). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan". medRxiv 10.1101/2022.06.28.22276794.
Scholia has a profile for KD-414 (Q110269777).
.svg){kind=small}
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |